Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
Provided By GlobeNewswire
Last update: Aug 14, 2025
FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia
Evaluation of strategic alternatives
Read more at globenewswire.comNASDAQ:NERV (8/26/2025, 1:01:53 PM)
2.41
+0.02 (+0.84%)
Find more stocks in the Stock Screener
